AOD-9604
- 99% Purity
- 2MG
$29.00
Earn 29 points ($1.45 back)
Multi-bottle discounts applied automatically in cart

Free Shipping on orders over $150

Free shipping

No returns or refunds
Returns or refunds are only accepted if the item arrives damaged, incorrect, or is lost during shipping.

Secure checkout
Certificate of Analysis

Scientific Overview
AOD-9604 is a modified fragment of the C-terminal region of human growth hormone (hGH), specifically amino acids 176-191, with the addition of a tyrosine residue at the N-terminus. It was developed to isolate the lipolytic activity of growth hormone from its growth-promoting effects. AOD-9604 received GRAS (Generally Recognized As Safe) designation from the US FDA in 2014.
Chemical Makeup
Molecular Formula
C₇₈H₁₂₃N₂₃O₂₃
Molecular Weight
1815.01 g/mol
CAS Number
221231-10-3
Other Names
Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191
Appearance
White to off-white lyophilized powder
Storage
Store refrigerated at 2–8°C. For extended storage, keep frozen at -20°C. Protect from light and moisture.
Research & Clinical Studies

Lipolytic Activity without Growth Effects
Preclinical studies observed that AOD-9604 interacts with lipolysis and lipogenesis pathways in adipose tissue without the diabetogenic, growth-promoting, or IGF-1-stimulating characteristics of full-length hGH. These observations were documented in both in vitro adipocyte assays and in vivo obese mouse models.

Phase 2 Clinical Evaluation
A randomized, double-blind, placebo-controlled phase 2b trial evaluated oral AOD-9604 in obese subjects over 24 weeks. The study assessed body weight change, waist circumference, and metabolic parameters. Results contributed to the compound's safety profile characterization.
References
- 1. Ng, F.M. et al. "Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone." Horm Res. 53(6):274-8 (2000). View
- 2. Heffernan, M. et al. "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice." Endocrinology. 142(12):5182-9 (2001). View